FACIT is a commercialization venture firm that builds companies with entrepreneurs to accelerate oncology innovation, with a portfolio that has attracted over $850 million in investment to Ontario. Blending industry experience, capital and the unsurpassed clinician-scientist network of its strategic partner the Ontario Institute for Cancer Research (OICR), FACIT capitalizes on the province’s investment in research and healthcare to the benefit of the local economy and patients worldwide. FACIT’s commercialization portfolio includes Turnstone Biologics, Fusion Pharmaceuticals, Triphase Accelerator and other biotechnology organizations. Cancer Breakthroughs. Realized. facit.ca.



Contact Information
Connie Chen, PhD
Senior Director, Strategy & Corporate Development
Tel: 647-260-7934
[email protected]

Latest

Mar 08, 2024, 10:00 ET FACIT and OBIO® partner on women-focused seed capital and entrepreneurship program

Synergies combine financing and entrepreneurial development resources to life sciences start-ups TORONTO, March 8, 2024 /CNW/ - On International Women's Day, FACIT and OBIO® are pleased to announce a ...

Nov 20, 2023, 11:15 ET Women-led health and biotech companies dominate FACIT's latest investments

Leadership of Ontario based Virano Therapeutics, Hyivy Health, Tenomix Inc., and DTPx Therapeutics are breaking down barriers TORONTO, Nov. 20, 2023 /CNW/ - On the globally-recognized Women's...

Nov 01, 2023, 11:00 ET FACIT appoints seasoned life science leaders to its Board of Directors

Drs. Maura Campbell and Laszlo Radvanyi further strengthen governance and commercialization TORONTO, Nov. 1, 2023 /CNW/ - FACIT is pleased to welcome two new directors to its Board, Dr. Maura...

Aug 02, 2023, 13:00 ET FACIT and T-CAIREM at the University of Toronto partner to commercialize medical AI

Scaling research ventures to drive impact for patients with cancer and the Ontario economy TORONTO, Aug. 2, 2023 /CNW/ - Together with the University of Toronto's Temerty Centre for Artificial...

Mar 31, 2023, 10:00 ET Innovative Cancer Immunotherapy Wins 2023 Falcons' Fortunes Pitch Competition

Celebrating a decade of backing Ontario entrepreneurs and advances in patient care TORONTO, March 31, 2023 /CNW/ - FACIT is pleased to announce that the winning pitch for the 10th anniversary...

Mar 29, 2023, 09:00 ET FACIT generates $1.5 billion in follow-on investment

A commercialization landmark for Ontario cancer innovations and patient impact TORONTO, March 29, 2023 /CNW/ - FACIT announced $1.5 billion in follow-on investment attracted to its portfolio of...

Sep 28, 2022, 09:00 ET FACIT's Prospects Fund fuels women's health and brain cancer therapies for Ontario patients

Seed-stage commercialization realizes value in the Province's health research and intellectual property TORONTO, Sept. 28, 2022 /CNW/ - FACIT congratulates Ontario-based start-ups Hyivy Health and...

Apr 28, 2022, 09:00 ET FACIT invests in OICR's groundbreaking approaches to integrated drug discovery and cancer informatics

Early-stage capital positions science and intellectual property for Ontario economic impact TORONTO, April 28, 2022 /CNW/ - FACIT announced two recent strategic investments from its Prospects...

Feb 04, 2022, 14:30 ET FACIT Announces Winner of 2022 Falcons' Fortunes Pitch Competition on World Cancer Day

Annual event showcases emerging entrepreneurs and FACIT's commitment to advance Ontario's most promising oncology innovations TORONTO, Feb. 4, 2022 /CNW/ - FACIT, a commercialization venture firm for ...

Nov 04, 2021, 09:00 ET FACIT broadens Executive-in-Residence program to capitalize on Ontario IP

Dr. Kuldeep Neote recruited for his decades of US-based pharma industry expertise TORONTO, Nov. 4, 2021 /CNW/ - FACIT, a commercialization-venture firm, announced the appointment of Dr. Kuldeep...

Sep 16, 2021, 09:00 ET FACIT's Prospects Fund invests in two emerging Ontario diagnostics for colorectal and prostate cancers

Early-stage capital drives commercialization and clinical validation in Province TORONTO, Sept. 16, 2021 /CNW/ - Two promising Ontario-based oncology innovations are the latest recipients of...

May 18, 2021, 09:00 ET FACIT leads seed round in Nanology Labs

Ontario start-up to commercialize smart nanomedicine technology for brain cancer TORONTO, May 18, 2021 /CNW/ - FACIT, a commercialization venture firm focused on advancing Ontario's top-tier oncology ...

Feb 04, 2021, 15:29 ET FACIT Crowns 2021 Winner of Falcons' Fortunes Pitch Competition; Announces Follow-on Investment in 2020 Winner, Bridge7 Oncology

Showcasing Ontario's emerging biotech entrepreneurs and driving value from intellectual property TORONTO, Feb. 4, 2021 /CNW/ - FACIT, a commercialization venture firm for Ontario cancer innovations,...

Jan 26, 2021, 09:30 ET FACIT welcomes life sciences executive Ken Newport to its Board; Director Shana Kelley appointed to the Order of Ontario

Blend of scientific, industry, investment and entrepreneurial expertise complements FACIT's leading role in growing Ontario's life sciences commercialization TORONTO, Jan. 26, 2021 /CNW/ - The Board...

Dec 10, 2020, 09:00 ET FACIT fuels promising made-in-Ontario breast cancer therapeutic and medtech innovations through Prospects Oncology Fund

Ontario First capital supports early stage commercialization of cancer intellectual property TORONTO, Dec. 10, 2020 /CNW/ - FACIT, Ontario's oncology commercialization venture firm, announced the...

Jun 23, 2020, 13:00 ET FACIT backs made-in-Ontario data science and medtech innovations through Prospects Oncology Fund

Replica Analytics and Sunnybrook's Czarnota Lab receive key seed funding to de-risk Ontario intellectual property TORONTO, June 23, 2020 /CNW/ - FACIT, a commercialization venture firm, announced the ...

Jun 09, 2020, 11:30 ET FACIT recognized with 2020 Venture Capital Regional Impact Award by the Canadian Venture Capital & Private Equity Association (CVCA)

Award acknowledges FACIT's commercialization impact in growing Ontario's life sciences industry TORONTO, June 9, 2020 /CNW/ - FACIT, a commercialization venture firm, has been nationally recognized...

Jan 28, 2020, 09:00 ET FACIT announces follow-on investments in Xpan Inc. and Nanology Labs through Compass Rose Fund

Prospects proof-of-concept funding elevates Ontario companies to seed stage investment TORONTO, Jan. 28, 2020 /CNW/ - FACIT, a commercialization venture firm focused on advancing Ontario's top-tier...

Nov 06, 2019, 09:00 ET FACIT launches assessment of venture philanthropy models to scale Canadian commercialization of cancer research

Ms. Donna Parr and Dr. Niclas Stiernholm recruited to broaden public/private equity expertise TORONTO, Nov. 6, 2019 /CNW/ - FACIT, a commercialization venture firm, reported on the expansion of its...

Oct 30, 2019, 09:00 ET FACIT and University of Toronto launch precision medicine company: Cellular Analytics

Next generation liquid biopsy platform to revolutionize companion diagnostics TORONTO, Oct. 30, 2019 /CNW/ - FACIT, a commercialization venture group, together with the University of Toronto ("U of...

Sep 26, 2019, 11:00 ET FACIT's Prospects Oncology Fund invests in Ontario-developed medical device and novel therapeutic platform technologies

Niche early-stage investment program seeds Ontario's developing pipeline of oncology assets TORONTO, Sept. 26, 2019 /CNW/ - Three promising Ontario-based oncology innovations are recipients of seed...

Jun 03, 2019, 09:00 ET FACIT portfolio reports $750M follow-on financing

$40M in seed investments leverages 19x new capital into Ontario cancer biotechnology commercialization TORONTO and PHILADELPHIA, June 3, 2019 /CNW/ - FACIT, an Ontario First investor-incubator, has...

Apr 08, 2019, 11:00 ET Entrepreneurs from Ontario's Nanology Labs and Xpan Inc. receive FACIT investment for early-stage cancer innovations

Latest recipients slated to accelerate Ontario's commercialization momentum are a 2018 finalist and 2019's winner of FACIT's Falcons' Fortunes pitch competition TORONTO, April 8, 2019 /CNW/ - FACIT,...

Jan 29, 2019, 07:00 ET FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-Class WDR5 Leukemia Therapy

Largest transaction to date for Canadian-discovered preclinical asset arises from Ontario collaborators TORONTO, Jan. 29, 2019 /CNW/ - Triphase Accelerator, together with its majority shareholder...

Jan 10, 2019, 09:00 ET FACIT Makes Follow-on Investment in AI-based genomics company, DNAstack

Capital leverages Ontario's strengths in genomics and informatics, deepens FACIT's tech portfolio TORONTO, Jan. 10, 2019 /CNW/ - FACIT, a business accelerator for Ontario oncology innovations,...

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE